Check-Cap partners with GE to manufacture ingestible x-ray device

Check-Cap, a clinical-stage medical diagnostics company, has entered into an agreement with GE Healthcare. The agreement is to develop and validate high-volume manufacturing for X-ray source production and assembly for Check-Cap’s ingestible capsule for colorectal cancer screening.

If all goes well, a collaboration for high-volume manufacturing as well as the distribution of the Check-Cap system is on the table. Check-Cap is conducting a multi-center clinical feasibility study and hopes to file for a CE Mark in the first half of 2017.

Bill Densel, CEO of Check-Cap, explained that GE Healthcare is a leader when it comes to development, manufacturing and distribution of products such as the Check-Cap system. “We believe that leveraging their experience and expertise provides us with a significant opportunity to meet our goal of increasing the time and cost efficiencies of production of our capsule for use in future clinical trials and commercialization,” he said in a statement.

Webinar

How ICON, Lotus, and Bioforum are Improving Study Efficiency with a Modern EDC

CROs are often at the forefront of adopting new technologies to make clinical trials more efficient. Hear how ICON, Lotus Clinical Research, and Bioforum are speeding database builds and automating reporting tasks for data management.

Check-Cap noted that nearly a third of the recommended adult population has never been screened for colorectal cancer or precancerous polyps. The Check-Cap system is meant to improve patient experience while eliminating some issues with current screening measures, such as bowel preparation, invasive procedure and stool handling. Those issues could also pose a barrier to test completion.

The capsule can be ingested and left to do its work as the patient goes about his or her normal day. The patient needs to take a small amount of standard contrast agent with meals.

The low-dose X-ray Radar device creates 2-D and 3-D images of the colon, using 360-degree angular scans that “see through” intestinal content. That means there is no need to clean out the bowels.

The capsule emits radiation equivalent to that of a standard chest X-ray. The information from the capsule is transmitted to a device on the patient’s back. The data is later analyzed by a physician. If nothing is detected, the patient does not require a standard colonoscopy. However, if the Check-Cap device does reveal polyps, a therapeutic colonoscopy would be prescribed.

- here's the press release

Related Articles: 
Israeli colon capsule maker reels in $24M in IPO and private placement
FDA gives Medtronic's PillCam OK for expanded indication on major risk patients
FDA rejects Otsuka, Proteus pill with medication adherence monitoring

Read more on

Suggested Articles

Sanofi will look to pull back from its three-year-old relationship with Verily and their virtual diabetes clinic, Onduo.

NASH leaders weigh in on the need for a drug for the disease and the challenges in getting it to patients.

AstraZeneca is linking up with DeepMatter, a big data firm focused on achieving reproducibility in chemistry, to help improve its compound synthesis.